AzTrials
AzTrials

ContraceptionIMPROVE-itNCT05521646

Implementing Best Practice Postpartum Contraceptive Services Through a Quality Improvement Initiative

A study testing Quality Improvement Collaborative in people with Contraception and Immigrant, run by Karolinska Institutet at 1 site in Sweden.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Immigrant women in Europe has reported lower use of effective contraception, higher risks of multiple births, and unintended pregnancies compared to native-born women. There is no evidence about this from a Swedish context nor about postpartum contraception. Read more about this study

Who is it for?
Ages 18 years and older, women onlyHealthy volunteers can take part
Conditions the study is for
Contraception, Immigrant, Post Partum
What is being tested?
Quality Improvement Collaborative
Could I receive a placebo?
No, everyone receives an active treatment
How many people
4,000 participants
Where
1 siteSweden
Study dates
5 Sep 2022to Sep 2025
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • Women only
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • Women coming for postpartum visit within 16 weeks post birth (live birth)

Who cannot join

  • Women who do not anticipate becoming sexually active with a male partner within six months.

Trial locations and contacts

1 site in 1 country.

Elin Larsson, PhD contact

+46702735609

elin.larsson@ki.se

Helena Kilander, PhD contact

helena.kilander@ki.se

Sweden1 site, 1 recruiting
  • Karolinska Inst.

    Stockholm, 17177

    Elin Larsson, PhD, +46702735609, elin.larsson@ki.se

    Recruiting

Other trials in Sweden

About this study

Official title: Promoting Equitable Reproductive Health: Implementing Best Practice Postpartum Contraceptive Services Through a Quality Improvement Initiative

Immigrant women in Europe has reported lower use of effective contraception, higher risks of multiple births, and unintended pregnancies compared to native-born women. There is no evidence about this from a Swedish context nor about postpartum contraception.

The purpose of this project is to promote equity in sexual and reproductive health (SRH) in Sweden by improving the quality of postpartum contraceptive counselling for and with immigrant women.

The Swedish Pregnancy Registry (SPR) will be used to determine if there are any differences in birth spacing and associated complications when comparing immigrant and Swedish-born women. Registration of contraceptive methods in the SPR will be introduced. The IMPROVE-it project will increase the understanding of challenges to contraceptive services postpartum, and how to overcome these.

Read the detailed description

This cRCT will be conducted at MHCs in the regions of Jönköping, Västra Götaland and Stockholm. The unit of randomization will be the clinics. The Swedish pregnancy Register (SPR) will be used to collect data on the women's choice of postpartum contraceptive method, and the proportion of women choosing an effective method will be compared between control and intervention clinics. A survey will be completed for both groups at the postpartum visit at MHCs within 16 weeks postpartum to evaluate the choice of contraceptive method and the counselling received, as well as six and 12 months after the visit to determine ongoing contraceptive use and satisfaction with the method. Furthermore, the follow up at six and 12 months will identify any unintended or planned pregnancy, abortion, or miscarriage that has happened since the postpartum visit.

Inclusion criteria: Women coming for postpartum visit within 16 weeks post birth (live birth). Exclusion criteria: Women below 18 years or having had a still birth. The intervention clinics will register women's choice of contraception during the postpartum MHC visit and participate in Quality Improvement Collaboratives (QIC) for 12 months. The control clinics will provide routine care, register women's choice of contraception in the SPR. Recruitment: Both type of clinics will register women's choice of contraception in the SPR at the postpartum visit within 16 weeks after giving birth and ask women for consent to participate in the study, i.e. respond to a self-administered questionnaire during the visit and be contacted for follow-up. Main outcome: Proportion of women who chose an effective contraceptive method, i.e. LARC or SARC, among immigrant and Swedish-born women, as registered in the SPR at the postpartum visit within 16 weeks after giving birth.

Secondary outcomes:

At enrolment:

  1. Women's satisfaction with the contraceptive counselling At six and 12 months after the postpartum visit:
  2. Use of contraception (and type)
  3. Satisfaction with the contraceptive method
  4. Experiences of unintended pregnancy, abortion, miscarriages since the postpartum visit
  5. Experiences of planned pregnancy since the postpartum visit

The Intervention: A QIC Initiative will be designed based on insights from the pilot study. Within the QIC, the MHCs will test evidence-based changes for contraceptive services during action periods and evaluate these during four learning seminars. Examples of evidence-based changes include using a visual aid to show contraceptive effectiveness translated to the most common languages or a person-centered counselling method based on approaches in MI and RPL. Four learning seminars will be carried out; inbetween them, there will be action periods when the midwives will test the changes made to contraceptive services in their MHC practice. Content of the learning seminars: Quality improvement methods-training; Updates on evidence-based contraceptive counselling; Feedback of data from the SPR on women's choice of contraception; Planning and evaluating tests of evidence-based changes at the MHC; Codeveloping contraceptive services in collaboration between midwives, researchers, and representatives from the target population. Part of the QIC is to continuously give data feedback to the clinics involved on women's choice of contraception. Data collection: The SPR will be used to collect and retrieve data for the primary outcome and background characteristics; a questionnaire will be used to collect data on the secondary outcome 1-2. At six and 12 months, a follow up questionnaire will be used to collect the secondary outcomes 2-5. This will be administered by SMS, email or mail. Three reminders will be sent.

Sample size and statistical power: The pilot study saw a 17% increase in the proportion of immigrant women choosing SARC/LARC. From this increase, we anticipate that at least the same share of the intervention group will be choosing SARC/LARC. Because of the cluster design, an intraclass correlation (ICC) factor affects and increases the sample size needed. The sample size was calculated to show a difference in proportions of participants choosing SARC/LARC in a two-group comparison between intervention and control groups. An assumed ICC of 0.05 was used, equivalent to the ICC observed in a similar study. To show the anticipated 15% difference in SARC/LARC choice with a 90% power at an α=0.05 (i.e. the probability of falsely rejecting a true null hypothesis), we need to include 14-15 clinics in each of the control and intervention groups, each contributing with an average of 100 participants. We will include a total of 29 clinics to allow for dropouts of clinics. The sample size calculations were performed by using the package clusterPower version 0.6.111 in R version 3.6.1. No power calculation was performed for secondary outcomes. Analysis: The analysis population will consist of all women in the cRCT. The primary analysis for the main outcome will be undertaken on an 'intention-to-treat' basis, i.e. all women with a recorded outcome will be included in the analysis and analyzed according to the group to which they were allocated, i.e. the proportion of women choosing SARC/LARC between our two randomized groups. We will further estimate the effect of the QIC using logistic regression analysis. Odds Ratios with 95% confidence intervals will be generated. A multivariate analysis will be performed to control for age, sociodemographic characteristics, and reproductive history.

Being tested
Quality Improvement Collaborative

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Quality Improvement CollaborativeOther

    Explore if a Quality Improvement Collaborative can increase the proportion of immigrant women who choose an effective postpartum contraceptive method

Study groups in NCT05521646
Study groupRoleWhat they receive
InterventionExperimentalQiC implemented
Receives: Other: Quality Improvement Collaborative
ControlNo interventionNot described

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Proportion of women who chose an effective contraceptive method, i.e. LARC or SARC, among immigrant and Swedish-born women.

    Data collection as registered in the Swedish pregnancy register at the postpartum visit within 16 weeks after giving birth.

    Measured: 12 months

Secondary outcomes (5)
  1. Womens satisfaction with the contraceptive counselling provided at the postpartum visit

    Data collection through a questionnaire (electronic, paper or by telephone together with an interpreter if needed) filled in by the participants (electronic or paper) or by a researcher (telephone).

    Measured: 12 months

  2. Participants´ use of contraception (and type) at six and 12 months follow-up

    A follow-up questionnaire will be used. Data collection through a questionnaire (electronic, paper or by telephone together with an interpreter if needed) filled in by the participants (electronic or paper) or by a researcher (telephone). The follow-up questionnaire will be administered by SMS, email or mail.

    Measured: 18-24 months

  3. Participants´ satisfaction with the contraceptive method at six and 12 months follow-up

    A follow-up questionnaire will be used. Data collection through a questionnaire (electronic, paper or by telephone together with an interpreter if needed) filled in by the participants (electronic or paper) or by a researcher (telephone). The follow-up questionnaire will be administered by SMS, email or mail.

    Measured: 18-24 months

  4. Participants´ experiences of unintended pregnancy, abortion, miscarriages since the postpartum visit, at six and 12 months follow-up

    A follow-up questionnaire will be used. Data collection through a questionnaire (electronic, paper or by telephone together with an interpreter if needed) filled in by the participants (electronic or paper) or by a researcher (telephone). The follow-up questionnaire will be administered by SMS, email or mail.

    Measured: 18-24 months

  5. Participants´ experiences of planned pregnancy since the postpartum visit, at six and 12 months follow-up

    A follow-up questionnaire will be used. Data collection through a questionnaire (electronic, paper or by telephone together with an interpreter if needed) filled in by the participants (electronic or paper) or by a researcher (telephone). The follow-up questionnaire will be administered by SMS, email or mail.

    Measured: 18-24 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted30 Aug 2022
  2. Study start5 Sep 2022
  3. Primary completionSep 2023 (estimated)
  4. Study completionSep 2025 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Health services research
Allocation
Randomised
Intervention model
Parallel groups
Model description
cluster randomized controlled trial
Masking
Single blind
Who is masked
Participant
Enrolment
4,000 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05521646
Sponsor's protocol ID
Dnr 2021-05962-01
Acronym
IMPROVE-it
Status last verified
Oct 2022
First submitted
25 Aug 2022
Last updated
10 Oct 2022
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No

Publications

  • Kilander H, Sorcher R, Berglundh S, Petersson K, Wangborg A, Danielsson KG, Iwarsson KE, Branden G, Thor J, Larsson EC. IMplementing best practice post-partum contraceptive services through a quality imPROVEment initiative for and with immigrant women in Sweden (IMPROVE it): a protocol for a cluster randomised control trial with a process evaluation. BMC Public Health. 2023 May 3;23(1):806. doi: 10.1186/s12889-023-15776-8.

    PubMed 37138268

Questions about this trial

What is this clinical trial studying?

A study testing Quality Improvement Collaborative in people with Contraception and Immigrant, run by Karolinska Institutet at 1 site in Sweden.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 10 Oct 2022. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Sweden. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Elin Larsson, PhD (+46702735609, elin.larsson@ki.se), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Proportion of women who chose an effective contraceptive method, i.e. LARC or SARC, among immigrant and Swedish-born women. (time frame: 12 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05521646, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Oct 2022.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in